A detailed history of Sei Investments CO transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Sei Investments CO holds 313,740 shares of SUPN stock, worth $11.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
313,740
Previous 337,658 7.08%
Holding current value
$11.4 Million
Previous $9.03 Million 8.3%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$25.77 - $35.16 $616,366 - $840,956
-23,918 Reduced 7.08%
313,740 $9.78 Million
Q2 2024

Aug 13, 2024

BUY
$25.99 - $33.85 $183,957 - $239,590
7,078 Added 2.14%
337,658 $9.03 Million
Q1 2024

May 07, 2024

BUY
$27.11 - $35.17 $1.76 Million - $2.28 Million
64,752 Added 24.36%
330,580 $11.3 Million
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $32,853 - $42,917
-1,446 Reduced 0.54%
265,828 $7.69 Million
Q3 2023

Nov 14, 2023

SELL
$27.57 - $32.91 $40,004 - $47,752
-1,451 Reduced 0.54%
267,274 $7.37 Million
Q2 2023

Aug 11, 2023

SELL
$29.91 - $38.73 $1.09 Million - $1.41 Million
-36,362 Reduced 11.92%
268,725 $8.08 Million
Q1 2023

May 12, 2023

BUY
$34.93 - $42.03 $1.31 Million - $1.58 Million
37,490 Added 14.01%
305,087 $11.1 Million
Q4 2022

Feb 10, 2023

BUY
$31.09 - $37.88 $717,432 - $874,118
23,076 Added 9.44%
267,597 $9.55 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $521,876 - $641,877
18,127 Added 8.01%
244,521 $8.28 Million
Q2 2022

Aug 15, 2022

BUY
$25.33 - $34.25 $82,195 - $111,141
3,245 Added 1.45%
226,394 $6.55 Million
Q1 2022

May 13, 2022

BUY
$28.51 - $32.9 $148,137 - $170,948
5,196 Added 2.38%
223,149 $7.22 Million
Q4 2021

Feb 14, 2022

SELL
$26.37 - $34.22 $190,734 - $247,513
-7,233 Reduced 3.21%
217,953 $6.36 Million
Q3 2021

Nov 12, 2021

BUY
$23.54 - $31.39 $617,642 - $823,610
26,238 Added 13.19%
225,186 $6.01 Million
Q2 2021

Aug 06, 2021

BUY
$26.72 - $33.19 $471,474 - $585,637
17,645 Added 9.73%
198,948 $6.13 Million
Q1 2021

May 12, 2021

SELL
$24.15 - $31.45 $984,667 - $1.28 Million
-40,773 Reduced 18.36%
181,303 $4.75 Million
Q4 2020

Feb 08, 2021

SELL
$17.7 - $25.81 $332,512 - $484,866
-18,786 Reduced 7.8%
222,076 $5.59 Million
Q3 2020

Nov 06, 2020

BUY
$20.2 - $25.05 $461,186 - $571,916
22,831 Added 10.47%
240,862 $5.02 Million
Q2 2020

Aug 17, 2020

SELL
$17.09 - $24.89 $1.64 Million - $2.39 Million
-95,876 Reduced 30.54%
218,031 $5.18 Million
Q2 2020

Aug 11, 2020

BUY
$17.09 - $24.89 $2.66 Million - $3.87 Million
155,365 Added 98.0%
313,907 $7.45 Million
Q1 2020

May 14, 2020

SELL
$14.45 - $24.69 $2.25 Million - $3.84 Million
-155,435 Reduced 49.51%
158,542 $2.85 Million
Q4 2019

Feb 06, 2020

SELL
$19.93 - $29.13 $102,719 - $150,136
-5,154 Reduced 1.62%
313,977 $7.45 Million
Q3 2019

Nov 12, 2019

BUY
$25.47 - $33.37 $2.48 Million - $3.25 Million
97,345 Added 43.89%
319,131 $8.75 Million
Q2 2019

Aug 14, 2019

BUY
$29.96 - $38.87 $459,975 - $596,771
15,353 Added 7.44%
221,786 $7.38 Million
Q1 2019

May 15, 2019

SELL
$32.77 - $41.99 $311,544 - $399,198
-9,507 Reduced 4.4%
206,433 $7.27 Million
Q4 2018

Feb 13, 2019

BUY
$30.84 - $49.51 $942,994 - $1.51 Million
30,577 Added 16.5%
215,940 $10.3 Million
Q3 2018

Nov 08, 2018

SELL
$42.7 - $56.55 $1.81 Million - $2.39 Million
-42,275 Reduced 18.57%
185,363 $9.34 Million
Q2 2018

Aug 03, 2018

SELL
$44.1 - $59.85 $196,862 - $267,170
-4,464 Reduced 1.92%
227,638 $13.6 Million
Q1 2018

May 11, 2018

BUY
$37.15 - $46.9 $131,733 - $166,307
3,546 Added 1.55%
232,102 $10.6 Million
Q4 2017

Feb 08, 2018

SELL
$36.4 - $42.6 $714,786 - $836,536
-19,637 Reduced 7.91%
228,556 $9.11 Million
Q3 2017

Nov 06, 2017

BUY
$36.75 - $49.65 $9.12 Million - $12.3 Million
248,193
248,193 $9.93 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.94B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.